Published in Medical Letter on the CDC and FDA, November 6th, 1995
Isoniazid has been the main chemoprophylactic agent for the prevention of active tuberculosis since the early 1960s, when criteria were established for its use. Studies have shown, however, that isoniazid-induced hepatitis occurs in up to 3 percent of patients treated with the agent who are aged 50 or over. For this reason, many clinicians avoid preventive tuberculosis therapy in patients older than 35.
In this study researcher...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.